My working diagnosis is panic disorder. The patient is a 34-year-old woman with three ED visits for palpitations, sweating, and a feeling of doom. Don't confirm it- challenge it. Which findings would argue against panic disorder, and where might I be anchoring?

Reading File

Finding Sources

Searching PubMed

panic disorder misdiagnosis cardiac arrhythmia

Reading File

Finding Sources

Searching PubMed

panic disorder misdiagnosis organic causes delayed diagnosis

Reading File

Finding Sources

Searching PubMed

pheochromocytoma panic attacks misdiagnosed psychiatric

Finding Sources

Searching PubMed

anchoring bias cognitive bias emergency department diagnostic error

I now have strong textbook and research grounding. Here is the full critical challenge:

Challenging Your Working Diagnosis of Panic Disorder

Panic disorder is a diagnosis of exclusion. Harrison's is explicit: "A diagnosis of panic disorder is made after a medical etiology for the panic attacks has been ruled out. A variety of cardiovascular, respiratory, endocrine, and neurologic conditions can present with anxiety as the chief complaint." Three ED visits without a definitive organic workup is not the same as a ruled-out organic cause - it may simply mean no one has looked hard enough yet.

Here is what should be making you uncomfortable:

1. Pheochromocytoma - the classic trap

The triad of paroxysmal palpitations + sweating + feeling of doom is textbook pheo. Robbins describes it precisely: "paroxysmal episodes... abrupt, precipitous elevation in blood pressure associated with tachycardia, palpitations, headache, sweating, tremor." Kaplan & Sadock notes that the combination of palpitations, headache, and profuse sweating is "the most sensitive and specific" symptom cluster for pheo.

Arguments against panic here: Did anyone check BP during an attack? Sustained or paroxysmal hypertension, headache, pallor, and postural hypotension are red flags. Has anyone ordered plasma or 24-hour urine metanephrines? In a 34-year-old woman with episodic autonomic surges, this is non-optional.

2. Paroxysmal Supraventricular Tachycardia (SVT) / Arrhythmias

Harrison's specifically lists paroxysmal atrial tachycardia as a cardiovascular condition to rule out with ECG and echocardiogram. SVT causes sudden-onset palpitations, near-syncope, and terror that patients describe in exactly the language of panic. Critically, the termination can be abrupt - unlike the typical gradual resolution of a panic attack (which takes ~1 hour per DSM criteria). WPW and other accessory pathway tachycardias are entirely possible in a young woman.

What to ask: Does the palpitation start and stop suddenly (on/off switch quality)? Does it respond to Valsalva? Has a resting ECG been done in all three visits - and was the delta wave looked for? Has she had continuous monitoring (Holter, event monitor, implantable loop recorder if needed)?

3. Thyrotoxicosis

Heat intolerance, palpitations, weight loss, tremor, and anxiety are the constellation. TSH is a cheap, easy test. In a woman of reproductive age this includes both Graves disease and Hashimoto's thyrotoxic phase. A normal TSH rules this out; has it been checked?

4. Hypoglycemia

Episodic sweating, palpitations, and feelings of doom triggered by the autonomic response to low glucose - especially relevant if attacks happen in a fasting state, post-exercise, or in the context of alcohol use or diabetes medications. Timing relative to meals is a simple but often unasked question.

5. Carcinoid Syndrome and Mastocytosis

Less common but worth flagging for completeness in someone with recurrent unexplained autonomic episodes. Carcinoid produces flushing, palpitations, and diarrhea; mastocytosis can produce episodic anaphylactoid reactions with profound cardiovascular symptoms and doom.

6. Neurologic Causes - Temporal Lobe Seizures

Ictal fear, autonomic discharge, and depersonalization can be indistinguishable from panic attacks on history alone. A patient will not describe them as seizures. The feeling of doom is actually a recognized aura of temporal lobe epilepsy.

7. Mitral Valve Prolapse

Harrison's mentions it specifically in the panic differential. Most cases of MVP are benign, but in the subset with significant regurgitation or dysautonomia, palpitations and chest pain can be prominent. An echocardiogram addresses this directly.

Where You Are Likely Anchoring

Anchoring bias is locking onto the first plausible framing (anxiety/panic) and interpreting all subsequent information through that lens. Several mechanisms are operating here:

Demographic anchoring: A 34-year-old woman with palpitations and emotional distress fits the cultural prototype of panic disorder. This is a known and well-documented bias; studies on cognitive bias in emergency medicine (Dargahi et al., 2022; Kunitomo et al., 2022 [PMID 36028810]) confirm anchoring as the most common diagnostic error in ED physicians.
Representativeness heuristic: Her presentation matches the textbook panic attack description so well that alternative diagnoses feel unnecessary. But pheo, SVT, and thyrotoxicosis were deliberately included in textbooks precisely because they match this description.
Search satisficing after three visits: Three visits creates a false sense that "if it were something serious, we'd have found it by now." But nothing in three ED visits for palpitations guarantees that anyone sent plasma metanephrines, did a 24-hour Holter, or measured BP during an attack.
Premature closure: Psychiatric diagnoses are especially vulnerable to premature closure because they require no confirmatory test - the diagnosis is made by symptom pattern, which the same organic diseases can replicate perfectly.
The "young woman" frame: This demographic is statistically over-represented in panic disorder diagnoses and simultaneously under-investigated for organic pathology. Several studies document that women's cardiovascular and endocrine symptoms are more frequently attributed to anxiety than men's.

What Would Actually Argue For Panic Disorder (Things to Confirm)

Before you're satisfied, you need to be able to say yes to most of these:

TSH, plasma/urine metanephrines, glucose during attack - normal
12-lead ECG in all three visits - no delta wave, no prolonged QT, no LBBB
BP during attacks documented - not hypertensive
Attack onset and offset gradual, not abrupt (not SVT quality)
No headache with attacks (reduces pheo likelihood)
No skin flushing, diarrhea, or wheezing (reduces carcinoid/mastocytosis)
No clear ictal features or post-event confusion (reduces seizure)
Family history of panic disorder (supporting genetic predisposition per Harrison's)
Attacks respond to the cognitive arousal cycle - anticipatory anxiety, agoraphobia developing over time

Bottom line: The symptoms are real and the panic disorder label may ultimately be correct, but right now the workup has been reactive rather than systematic. A 34-year-old woman with three visits and no clear organic exclusion has not had panic disorder confirmed - she has had an organic cause not yet tested for. Pheo and SVT, in particular, deserve active exclusion before you commit to a psychiatric label and treatment pathway.

Harrison's Principles of Internal Medicine 22E (2025), Anxiety Disorders / Panic Disorder section
Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Adrenal Disorders section
Robbins, Cotran & Kumar Pathologic Basis of Disease, Pheochromocytoma
Kunitomo K et al. Cognitive biases in the emergency room. BMC Emerg Med. 2022 [PMID 36028810]

give me a proper treatment plan

Asking for Preferences

Finding Sources

Searching PubMed

panic disorder treatment guidelines SSRI CBT

Reading File

Finding Sources

Searching PubMed

panic disorder pharmacotherapy psychotherapy combined treatment efficacy

Finding Sources

Searching PubMed

panic disorder CBT cognitive behavioral therapy randomized controlled

Reading File

Reading Article

PMID: 35049483

Reading Article

PMID: 37132646

Strong evidence base assembled. Here is the full treatment plan.

Treatment Plan: Panic Disorder

Patient: 34-year-old woman, confirmed diagnosis after organic exclusion, no known comorbidities

Phase 1 - Acute Stabilization (Weeks 1-4)

Pharmacotherapy: Start an SSRI

First-line choice: Sertraline (best tolerability profile at low doses, FDA-approved for panic disorder)

Start at 25 mg/day for the first week (half the standard starting dose - panic disorder patients are particularly sensitive to initial activating effects and a full dose can paradoxically worsen anxiety and worsen early treatment dropout)
Titrate to 50 mg/day at week 2 if tolerated
Target therapeutic range: 50-100 mg/day; some patients need up to 200 mg
Warn her explicitly that anxiety and palpitations may briefly worsen in the first 1-2 weeks - this is not a reason to stop. Failure to warn about this causes early discontinuation and reinforces her fear

Alternatives if sertraline not tolerated or preferred:

Paroxetine 10 mg/day start → 20-40 mg (≥40 mg may be needed; FDA-approved); note: more anticholinergic, discontinuation syndrome more severe
Fluoxetine 5-10 mg/day start → 20 mg (longer half-life, easier discontinuation)
Venlafaxine XR 37.5 mg/day start → 75-225 mg (FDA-approved; good option if depression co-emerges)

Maudsley Guidelines are specific: "Doses of citalopram, sertraline towards the bottom of the antidepressant range give the best balance between efficacy and adverse effects. Efficacy of SSRIs (but not SNRIs) increases across the licensed dose range in anxiety disorders."

Short-term Benzodiazepine Bridge (optional, time-limited)

She has had three ED visits - anticipatory anxiety is likely already significant. A brief benzodiazepine bridge while the SSRI takes effect (2-6 weeks onset) is clinically reasonable.

Clonazepam 0.25-0.5 mg twice daily for maximum 4 weeks, then taper
Augmentation with clonazepam produces faster early response but not greater overall magnitude per the Maudsley evidence
Set a clear exit plan from day one - "this is a bridge, not a long-term medication"
NICE does not recommend long-term benzodiazepines for panic disorder; document the rationale and time-limit explicitly
Avoid alprazolam as first choice (shorter half-life, higher dependence risk, more pronounced rebound anxiety)

Phase 2 - Psychotherapy (Start at week 2-4, run concurrently with medication)

Cognitive Behavioral Therapy (CBT) - First-Line Psychological Treatment

CBT has the strongest evidence base. A 2022 network meta-analysis of 136 RCTs (Papola et al., Br J Psychiatry) found CBT superior to treatment as usual with moderate-confidence evidence (SMD -0.67); it was the only intervention that remained efficacious after removing high-bias trials. Short-term psychodynamic therapy is an alternative if CBT is inaccessible.

CBT components specific to panic disorder:

Psychoeducation - Explain the panic cycle: somatic sensation → catastrophic misinterpretation → arousal → more sensation. This alone has therapeutic effect. She needs to understand that palpitations will not kill her, and that the ED visits have reinforced avoidance.
Controlled breathing / diaphragmatic breathing - Counters hyperventilation that prolongs attacks. Teach in-session, assign as daily practice.
Cognitive restructuring - Identify and challenge catastrophic cognitions ("I'm dying," "I'm losing control"). Keep a thought diary between sessions.
Interoceptive exposure - Deliberately induce mild somatic sensations (spinning, breathing through a straw, running up stairs) in session to break the fear-of-fear cycle. This is the most potent component for panic disorder specifically.
In vivo exposure - Systematic, graded exposure to avoided situations (e.g., driving, crowded places, exercise). If agoraphobia is emerging after three ED visits, this needs to start early.

Format: A 2023 network meta-analysis (Papola et al., Psychol Med, 74 RCTs, n=6699) found no efficacy difference between face-to-face individual, face-to-face group, and guided self-help. Guided self-help is a viable option if therapist access is a barrier - unguided self-help alone is not sufficient.

Duration: 12-15 structured sessions per Harrison's; most protocols run 10-16 weeks.

Phase 3 - Monitoring and Titration (Months 1-3)

Timepoint	Action
Week 2	Brief telephone or portal check-in. Tolerability? Any suicidal ideation? (SSRIs carry a warning, especially in the first weeks)
Week 4	First in-person review. Assess for any early response; titrate SSRI dose upward if no response and well-tolerated. Begin benzodiazepine taper if bridge was used.
Week 8	Review attack frequency and severity. Assess for comorbid depression - 75% of panic disorder patients meet criteria for major depression at some point (Harrison's).
Week 12	Formal response assessment. If inadequate, increase SSRI dose before switching.
Month 3	Consider augmentation with aripiprazole, divalproex, or pindolol if treatment-resistant

Response targets: Reduction in attack frequency and intensity; reduced anticipatory anxiety; re-engagement with avoided activities. Full remission is possible but partial response is common - do not escalate prematurely.

Phase 4 - Maintenance and Relapse Prevention

Maintain pharmacotherapy for at minimum 12-18 months after achieving a satisfactory response (Harrison's: "1-2 years to prevent relapse"). The Maudsley cites convincing naturalistic benefit for at least 3 years.
Warn her: "Less than half of patients remain well after medication is withdrawn" (Maudsley). Taper slowly when the time comes - do not stop abruptly.
CBT skills are protective against relapse after medication discontinuation in a way that medication alone is not - this is a major argument for doing both.
Overall success rate with combined treatment: 75-85% for attack reduction, though complete remission is lower (Harrison's).

Safety Netting

Tell her explicitly:

The first 1-2 weeks on the SSRI may feel worse before it feels better. This is expected and not a sign the medication is wrong.
If she has chest pain with exertion (not at rest/panic), new neurological symptoms, or sustained headache with attacks, she should be re-evaluated - the organic workup was thorough, but symptoms can change.
If she develops suicidal thoughts, increased depression, or behavioral disinhibition on the SSRI, contact you immediately.
ED visits for panic attacks are counterproductive in the medium term - they reinforce avoidance and the sick-role. Having a clear action plan for attacks (breathing technique, grounding) reduces this. Consider giving her a written self-management card.

Patient Education - Key Points to Communicate

Panic disorder is a medical condition, not a character flaw or weakness. The brain's alarm system has become miscalibrated - it fires in the absence of real danger.
The palpitations and sweating are real physical sensations - she is not imagining them. They are caused by adrenaline release, which is harmless.
Avoidance maintains the disorder. Every time she leaves a situation during a panic attack, the brain learns that the situation was dangerous. Exposure breaks that learning.
Recovery takes months, not days. Setbacks (individual panic attacks) are normal and do not mean treatment has failed.

Summary Table

Domain	Intervention	Notes
Pharmacotherapy	Sertraline 25 mg → 50-100 mg	Start low, titrate slowly
Bridge	Clonazepam 0.5-1 mg/day	Maximum 4 weeks, taper with plan
Psychotherapy	CBT, 12-15 sessions	Interoceptive + in vivo exposure required
Format	Individual or group CBT	Guided self-help if access limited
Duration	12-18 months minimum post-response	Discuss taper risk explicitly
Monitoring	Weeks 2, 4, 8, 12	Watch for depression emergence
Safety net	Written attack plan, red flag symptoms	Reduce ED re-attendance

Sources:

Harrison's Principles of Internal Medicine 22E (2025), Panic Disorder treatment section
The Maudsley Prescribing Guidelines in Psychiatry, 15th Ed, Anxiety Disorders
Papola D et al. Comparative efficacy and acceptability of psychotherapies for panic disorder. Br J Psychiatry. 2022 [PMID 35049483]
Papola D et al. CBT delivery formats for panic disorder. Psychol Med. 2023 [PMID 37132646]
Schiele MA et al. Treatment options in treatment-resistant anxiety disorders. Psychother Psychosom. 2026 [PMID 40946318]

This is a shared conversation. Sign in to Orris to start your own chat.